IGRT 2016 Madrid

First page Table of contents Previous page 178-179 Next page Last page

The proof is in the pudding:

Margins too large ?? • No (few) marginal recurrence • Might limit dose escalation and lead to in-field recurrence

Due et al R&O 2014

Made with